SCHEMBL4338161

SCHEMBL4338161

CCC(O)(CC)[C@@H](Cc1ccccc1)NC(=O)C(=O)N[C@H](Cc1ccccc1)C(O)(CC)CC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
CTRB1 P17538 5/20 0.47
MMP9 P14780 2/20 0.44
MMP8 P22894 2/20 0.44
MMP14 P50281 2/20 0.44
RIPK1 Q13546 1/20 0.44
LMNA P02545 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 1/20 0.42
TAAR1 Q96RJ0 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4341539 0.89 NPC1 (0.46) NPSR1NPC1RAB9ACTRB1
SCHEMBL4332917 0.88 NPC1 (0.45) NPSR1NPC1RAB9ACTRB1MMP9
SCHEMBL4330855 0.86 NPSR1 (0.44) NPSR1NPC1RAB9ACTRB1RIPK1
SCHEMBL4339597 0.85 NPSR1 (0.53) NPSR1NPC1RAB9ACTRB1MMP9
SCHEMBL4330746 0.85 NPSR1 (0.45) NPSR1NPC1RAB9ACTRB1MMP9
SCHEMBL4332764 0.83 NPC1 (0.50) NPSR1NPC1RAB9ACTRB1MMP9
SCHEMBL1152803 0.83 CTRB1 (0.41) NPSR1NPC1RAB9ACTRB1LMNA
SCHEMBL4336554 0.82 PSMB5 (0.45) NPSR1NPC1RAB9ACTRB1MMP9
SCHEMBL1153212 0.81 MME (0.40) NPSR1NPC1RAB9ACTRB1POLB
SCHEMBL1153392 0.81 MME (0.42) NPSR1NPC1RAB9ACTRB1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612236-B2 Method for producing optically active bisamidoalcohol compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-11-03 US disclosed
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced SUMITOMO CHEMICAL COMPANY, LIMITED 2007-05-03 US disclosed
EP-1698616-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070100163-A1 Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced CCNL2, ARL1, ACSL3 NPSR1 2065/4885NPC1 3582/4885RAB9A 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.